We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+21.26%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$3.77B
AUM Growth
+$720M
(+24%)
Cap. Flow
+$280M
Cap. Flow
% of AUM
7.43%
Top 10 Holdings %
Top 10 Hldgs %
22.38%
Holding
294
New
116
Increased
45
Reduced
52
Closed
77
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$115M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$93.9M |
| 3 |
NXP Semiconductors
NXPI
|
+$57.1M |
| 4 |
Eli Lilly
LLY
|
+$51.1M |
| 5 |
Qorvo
QRVO
|
+$47.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microchip Technology
MCHP
|
+$72.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$66.5M |
| 3 |
Amazon
AMZN
|
+$65.6M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$58.8M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$53.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 42.9% |
| 2 | Technology | 32.83% |
| 3 | Communication Services | 8.98% |
| 4 | Financials | 3.92% |
| 5 | Consumer Discretionary | 3.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Universal Health Services
UHS
$10.2B
| $39.5M | 1.05% |
+287,215
| New | +$35.7M |
|
27
Becton Dickinson
BDX
$45.6B
| $39.2M | 1.04% |
160,623
+108,513
| +208% | +$25.3M |
|
|
SYNH
28
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $33.4M | 0.89% |
489,893
+376,774
| +333% | +$23.5M |
|
29
Revolution Medicines
RVMD
$39.9B
| $32M | 0.85% |
807,130
+779,219
| +2,792% | +$30.8M |
|
30
Cirrus Logic
CRUS
$6.53B
| $31.8M | 0.84% |
387,244
+248,833
| +180% | +$18.7M |
|
31
Pinterest
PINS
$13.4B
| $31.1M | 0.83% |
+472,105
| New | +$28.3M |
|
32
NVIDIA
NVDA
$4.86T
| $30.6M | 0.81% |
2,346,200
+1,746,080
| +291% | +$23.4M |
|
33
Nutanix
NTNX
$16B
| $30.4M | 0.81% |
+954,706
| New | +$25.9M |
|
34
Lyft
LYFT
$6.02B
| $30.4M | 0.81% |
618,309
-508,923
| -45% | -$18.5M |
|
35
Ciena
CIEN
$53.4B
| $30.3M | 0.8% |
573,570
+433,894
| +311% | +$19.3M |
|
|
DRNA
36
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $29.9M | 0.79% |
1,358,796
+885,189
| +187% | +$19.5M |
|
37
Danaher
DHR
$137B
| $29.9M | 0.79% |
151,911
-13,191
| -8% | -$2.64M |
|
38
HCA Healthcare
HCA
$87.2B
| $29.8M | 0.79% |
+181,151
| New | +$26.5M |
|
39
Cardinal Health
CAH
$53.9B
| $29.5M | 0.78% |
550,219
+287,252
| +109% | +$14.9M |
|
40
Cooper Companies
COO
$14.1B
| $29.4M | 0.78% |
324,000
+162,428
| +101% | +$13.9M |
|
|
ZGNX
41
DELISTED
Zogenix, Inc.
ZGNX
| $28.9M | 0.77% |
1,444,586
+423,547
| +41% | +$8.66M |
|
42
Mercado Libre
MELI
$95.2B
| $28.7M | 0.76% |
+17,132
| New | +$24.2M |
|
43
Viavi Solutions
VIAV
$9.12B
| $28.3M | 0.75% |
1,890,440
-682,446
| -27% | -$9.07M |
|
|
CCC
44
CCC Intelligent Solutions
CCC
$3.59B
| $28M | 0.74% |
+2,110,820
| New | +$25.7M |
|
45
Teleflex
TFX
$6.05B
| $26M | 0.69% |
63,235
+18,415
| +41% | +$6.79M |
|
46
Fox Class A
FOXA
$24.5B
| $25.6M | 0.68% |
878,048
+429,655
| +96% | +$12M |
|
47
Avantor
AVTR
$9.32B
| $25.5M | 0.68% |
907,193
+164,786
| +22% | +$4.25M |
|
|
HOLX
48
DELISTED
Hologic
HOLX
| $25.3M | 0.67% |
347,724
+38,804
| +13% | +$2.74M |
|
49
NetApp
NTAP
$35B
| $24.8M | 0.66% |
374,600
+261,383
| +231% | +$13.8M |
|
50
Marvell Technology
MRVL
$168B
| $24.5M | 0.65% |
+514,444
| New | +$22.3M |
|
Similar funds
PAM
TCIIS
UIM
Woodline Partners's Q4 2020 Portfolio in Review
As of Q4 2020, Woodline Partners held 294 positions worth $3.77B, up 24% from $3.05B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Woodline Partners deployed $280M of net new capital in Q4 2020, opening 116 new positions and adding to 45 existing holdings. Its largest new stake was Amgen: 500,520 shares worth $115M.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 45% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $58.8M trimmed.
- Woodline Partners's largest Q4 2020 buy was Amgen: 500,520 shares worth $115M.
- Woodline Partners added most to Eli Lilly in Q4 2020, an estimated $51.1M increase.
- Woodline Partners's biggest Q4 2020 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $58.8M.
- Woodline Partners fully exited Microchip Technology in Q4 2020, selling an estimated $72.6M.
- Woodline Partners's ten largest holdings make up 22% of its $3.77B portfolio in Q4 2020.
- Woodline Partners opened 116 new positions and closed 77 in Q4 2020.
- Woodline Partners's portfolio value rose 24% quarter-over-quarter to $3.77B.
Based on Woodline Partners's 13F filing for Q4 2020, filed 16 Feb 2021.